Expansion Opportunities Leverage Neuronetics’ growing interventional psychiatry network and partnerships (Greenbrook platform, TheTMScenter of NJ, Medisun collaboration) to target clinics expanding TMS services and related neurohealth therapies.

Financial Growth Strong revenue momentum with Q1 2026 revenue at 34.5M and an overall revenue range of 50M-100M, suggesting readiness for scaled system sales, service contracts, and expanded installation pipelines.

Leadership Realignment Recent CFO appointment and executive leadership changes indicate strategic focus on financial discipline and corporate growth; align value propositions around capital efficiency, reimbursements, and scalable deployment models.

Technology & IP NeuroStar remains the market leader with a broad installed base and 6.4 million treatments performed, presenting opportunities to upsell system upgrades, integration with clinic workflows, and data-enabled outcomes reporting for payer negotiations.

Global & Payer Reach Global markets and international partnerships alongside payer-facing safety and prescribing information present avenues to expand international deployments, clinician training packages, and bundled financing options for clinics seeking breadth of coverage.